Vapotherm, Inc. (VAPO): Price and Financial Metrics


Vapotherm, Inc. (VAPO): $20.90

0.12 (+0.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VAPO POWR Grades


  • Sentiment is the dimension where VAPO ranks best; there it ranks ahead of 60% of US stocks.
  • The strongest trend for VAPO is in Stability, which has been heading up over the past 51 weeks.
  • VAPO ranks lowest in Quality; there it ranks in the 4th percentile.

VAPO Stock Summary

  • Vapotherm Inc's stock had its IPO on November 14, 2018, making it an older stock than only 7.42% of US equities in our set.
  • The ratio of debt to operating expenses for Vapotherm Inc is higher than it is for about 26.07% of US stocks.
  • As for revenue growth, note that VAPO's revenue has grown 59.31% over the past 12 months; that beats the revenue growth of 89.18% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Vapotherm Inc are PWFL, ESTA, ATRI, AXGN, and CSII.
  • VAPO's SEC filings can be seen here. And to visit Vapotherm Inc's official web site, go to www.vapotherm.com.

VAPO Valuation Summary

  • VAPO's price/earnings ratio is -12.5; this is 134.25% lower than that of the median Healthcare stock.
  • Over the past 34 months, VAPO's EV/EBIT ratio has gone down 4.7.
  • Over the past 34 months, VAPO's EV/EBIT ratio has gone down 4.7.

Below are key valuation metrics over time for VAPO.

Stock Date P/S P/B P/E EV/EBIT
VAPO 2021-08-31 5.8 7.7 -12.5 -12.6
VAPO 2021-08-30 5.9 7.8 -12.7 -12.8
VAPO 2021-08-27 5.7 7.6 -12.4 -12.5
VAPO 2021-08-26 5.7 7.7 -12.5 -12.5
VAPO 2021-08-25 5.4 7.3 -11.8 -11.9
VAPO 2021-08-24 5.5 7.3 -11.9 -12.0

VAPO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VAPO has a Quality Grade of F, ranking ahead of 4.21% of graded US stocks.
  • VAPO's asset turnover comes in at 0.636 -- ranking 62nd of 184 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows VAPO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.636 0.505 -0.633
2021-03-31 0.680 0.511 -0.536
2020-12-31 0.688 0.501 -0.623
2020-09-30 0.624 0.493 -0.583
2020-06-30 0.572 0.480 -0.610
2020-03-31 0.521 0.462 -0.703

VAPO Stock Price Chart Interactive Chart >

Price chart for VAPO

VAPO Price/Volume Stats

Current price $20.90 52-week high $38.46
Prev. close $20.78 52-week low $16.64
Day low $20.63 Volume 111,200
Day high $21.29 Avg. volume 260,320
50-day MA $25.39 Dividend yield N/A
200-day MA $24.96 Market Cap 543.55M

Vapotherm, Inc. (VAPO) Company Bio


Vapotherm Inc. Vapotherm, Inc. is a global medical technology company. The Company is focused on the development and commercialization of its high velocity nasal insufflations (Hi-VNI) technology products that are used to treat patients suffering from respiratory distress. Its Hi-VNI technology delivers noninvasive ventilatory support by providing heated, humidified and oxygenated air at a high velocity to patients through a comfortable small-bore nasal interface. Its Precision Flow systems uses its Hi-VNI technology. It offers three versions of its Precision Flow systems: Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its Precision Flow systems include a capital unit, a single-use disposable and a nasal interface. Its Precision Flow versions are integrated systems that provide precise user control of temperature, air flow and percentage oxygen through a one-button interface.


VAPO Latest News Stream


Event/Time News Detail
Loading, please wait...

VAPO Latest Social Stream


Loading social stream, please wait...

View Full VAPO Social Stream

Latest VAPO News From Around the Web

Below are the latest news stories about Vapotherm Inc that investors may wish to consider to help them evaluate VAPO as an investment opportunity.

Shareholders in Vapotherm (NYSE:VAPO) have lost 14%, as stock drops 15% this past week

The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that...

Yahoo | September 29, 2021

Vapotherm Stock: Can HVT 2.0 Lead to Gains?

I am neutral on Vapotherm (VAPO), as its attractive stock price and high potential pipeline make it look attractive. However, the company has a lot of risk stemming from its declining revenues and widening losses. Vapotherm is a publicly held corporation that manufactures advanced respiratory technology for ventilator support. The company is known for developing the first non-invasive, humidified high-velocity therapy nasal cannula system for patients suffering from respiratory distress, who cannot tolerate breathing masks. Strengths Vapotherm recently announced it has received 510(k) clearance from the FDA for its innovative next-generation system, the HVT 2.0. This particular system is designed to provide high flow therapy using an integrated air source.

Samuel Smith on TipRanks | September 20, 2021

Vapotherm Increases Fiscal Year 2021 Revenue Outlook and Announces Expansion of Production Capacity

EXETER, N.H., September 08, 2021--Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), today updated its fiscal year 2021 revenue expectations and announced it will expand its disposables production capacity. The expansion of disposables production capacity will include the addition of assembly lines in Mexico which will increase capacity by 75% without adding material fixed costs and prepare the Company for the possibility that COVID-19 becomes a permanent part of the respiratory landsc

Yahoo | September 8, 2021

Vapotherm Announces FDA 510(k) Clearance for HVT 2.0 Next Generation Platform

EXETER, N.H., August 30, 2021--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced it has received 510(k) clearance from the US Food and Drug Administration for HVT 2.0. This next generation system is designed to provide high velocity therapy using an integrated air source, eliminating the need for wall air or any pressurized air source. It is estimated that 50% of U.S. hospital beds don’t have wall air. When paired with an oxygen source, the HVT 2.0 will support patien

Yahoo | August 30, 2021

Vapotherm (VAPO) Reports Q2 Loss, Tops Revenue Estimates

Vapotherm (VAPO) delivered earnings and revenue surprises of -4.69% and 13.45%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 9, 2021

Read More 'VAPO' Stories Here

VAPO Price Returns

1-mo -26.62%
3-mo -4.08%
6-mo -1.88%
1-year -29.63%
3-year N/A
5-year N/A
YTD -22.19%
2020 120.89%
2019 -39.05%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.96 seconds.